SCIENTIFIC CAPITAL PROGRAMME / MASTER DPR

COMPUTATIONAL BIOLOGY · BIOLOGICS · GENOMICS · PANDEMIC READINESS

AI-native life science,
designed as national-scale infrastructure.

Katral Advanced Biotech AI Lab is a master-planned research and manufacturing programme—not an operating laboratory. The source dossier specifies a UAE flagship campus, an AI and computational-biology core, high-containment research, GMP biologics and an Africa access network.

PHASE-I CONCEPT100-ACRE UAE CAMPUS
CAPITAL RANGE IN DPR$250M–$500M+
PHASE-II MANDATEAFRICA ACCESS NETWORK
MATURITYMASTER PLAN / PRE-FEASIBILITY

One campus.
Five coupled capabilities.

The programme combines computation, wet-lab research, containment, manufacturing and access strategy so discoveries can move through a controlled translation path.

01AI drug discovery

GPU-enabled molecular design, high-throughput screening and digital-twin research.

02Genomics

Sequencing, bioinformatics, CRISPR engineering, mRNA and synthetic-biology platforms.

03Virology

Blueprinted BSL-3/4 containment, mutation modelling and rapid candidate generation.

04Biologics

Recombinant insulin, heat-stable formulation research and injectable development.

05GMP translation

Pilot-to-commercial bioreactors, purification, fill-finish and lyophilisation.

Biosecurity-first zoning.
Expandable by design.

25 ACRES

Central R&D + AI

AI drug discovery, bioinformatics, molecular wet labs, collaboration floors and repeatable 1,000–2,000 sqm lab modules.

15 ACRES

GMP manufacturing

Biologic production, insulin fermentation and purification, injectable fill-finish and lyophilisation lines.

10 ACRES

High-containment virology

Negative-pressure suites, airlocks, HEPA exhaust, decontamination and separated high-risk movement routes.

08 ACRES

AI data centre

GPU clusters, secure genomic-data vaults, hybrid-cloud links, dedicated power, UPS and future solar integration.

10 ACRES

Utilities + waste

Water-for-injection, effluent treatment, biohazard waste, central HVAC and redundant utilities.

22 ACRES

Scientists + training

Residences, visiting faculty facilities, training institute and global conference capability.

10 ACRES

Expansion + buffer

Green separation, climate adaptation and capacity reserved for later research or manufacturing modules.

MODULAR STANDARD

Controlled adaptability

Plug-and-play services and convertible lab blocks enable R&D-to-pilot transitions without redesigning the campus.

Compute → evidence →
manufacturing → access.

01Target discovery

AI and bioinformatics prioritise molecules, proteins and disease mechanisms.

02Wet-lab validation

Molecular biology and genomics teams test hypotheses under controlled protocols.

03Preclinical evidence

Candidate safety, mechanism and manufacturability are assessed.

04Clinical pathway

Ethics, regulators and partner institutions govern human-study progression.

05GMP production

Qualified processes transfer candidates into pilot and commercial manufacturing.

06Africa access

Regional facilities, government procurement and local workforce development extend availability.

Every transition requires independent scientific review, bioethics governance and jurisdiction-specific regulatory approval. BSL-4 and GMP capabilities are programme targets; the site does not represent them as currently commissioned.

A programme that advances
only when evidence does.

GATE 01

Pre-feasibility

Government alignment, land and utility studies, biosafety case, scientific advisory board and priority product definition.

GATE 02

Detailed design

EPC and specialist lab design, regulatory pathway, equipment validation, workforce plan and phaseable capital schedule.

GATE 03

Commissioning

Construction qualification, facility certification, biosafety verification, quality systems and staged operational authorisation.

CURRENT MATURITYMASTER DPR
SOURCE CAPITAL RANGE$250M–$500M+ for Phase I, including land, construction, equipment, AI systems and working capital
IMMEDIATE NEXT PROOFGovernment MoU, independent pre-feasibility study and regulator-led facility pathway
SOURCE BASIS / SK\Katral Advanced Biotect AI LAB master document and extracted DPR. Budget ranges are preliminary source estimates, not a financing commitment or third-party valuation.
SCIENTIFIC PARTNERS

Build the programme around governance, not ambition alone.

Target partners include government science authorities, GMP and biosafety designers, hospital research networks, regulators, manufacturing specialists and long-horizon capital.

CONNECTED INFRASTRUCTURE

Explore privacy-preserving provenance for models, genomic proofs and orbital data custody.

Trust & orbital vaults →